PHASE 2B STUDY IN CHF (REC-DUT-003)
The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with Heart Failure and reduced Ejection Fraction (HFrEF).
Status of Study
Planned to start in late 2021.
Study Design
The double-blind, randomized, placebo-controlled study (Phase 2B) will evaluate both safety and efficacy of dutogliptin in combination with G-CSF as an adjunct treatment for patients with Heart Failure and reduced Ejection Fraction (HFrEF) of <40%. Patients will be in disease stage NYHA Class II and III (mild to marked symptoms and limitation during ordinary activity).